[A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].
The patient was a 68-year-old woman who underwent left partial mastectomy on February 1999. The stage was T2N1. There were positive for estrogen and progesterone receptors in the tumor. After operation, adjuvant therapy consisting of oral administration of tamoxifen and radiation was performed. On February 2005, she felt dyspnea and right femoral pain. After examinations, she was diagnosed as recurrent breast cancer with pleuritis carcinomatosa and bone metastasis. The patient was treated with oral administration of anastrozole and pamidronate disodium 90 mg intravenously every 4 weeks, radiation of her right femur, and OK-432 injection into the intrapleural cavity. On November 2005, she felt general fatigue and anorexia. CT examination revealed multiple liver metastases. She was treated with oral combination chemoendocrine therapy with capecitabine (2,400 mg/day) and MPA (600 mg/day). After the four courses, multiple liver metastases were remarkably reduced in the CT findings. After twelve courses, the partial response continued. No adverse reactions occurred except for gain in weight of grade 1. It is suggested that this oral combination chemoendocrine therapy may be useful for recurrent breast cancer with consideration for treatment effectiveness and the quality of life of the patient.
Konishi
Kazuya
K
Dept. of Surgery, Kushiro City General Hospital.
Hasegawa
Naoto
N
Kawabata
Makoto
M
Abeshima
Shigeki
S
Ichimura
Tatsunosuke
T
Kaneko
Hiroyuki
H
Nakayama
Tomohide
T
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D000069287:Capecitabine; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D003841:Deoxycytidine; D000069287:Capecitabine; D017258:Medroxyprogesterone Acetate; D005472:Fluorouracil